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Abstract: Patient reported outcome measures (PROMs) provide a valuable means of measuring outcomes 
subjectively from a patient’s perspective, facilitating the assessment of service quality across healthcare 
providers, and assisting patients and clinicians in shared decision making. The primary aim of this systematic 
review was to critically appraise all historic studies evaluating patient reported quality of life, in adult 
patients undergoing laparoscopic cholecystectomy for symptomatic gallstones. The secondary aim was to 
perform a quality assessment of cholecystectomy-specific PROM-validation studies. A literature review 
was performed in PubMed, Google ScholarTM, the Cochrane Library, Medline, CINAHL, EMBASE and 
PsychINFO databases up to September 2017. Study characteristics, PROM-specific details and a bias 
assessment were summarised for non-validation studies. A COnsensus-based Standards for the selection of 
health Measurement INstruments (COSMIN) analysis was performed to assess the methodological quality 
of identified PROM-validation studies. Fifty one studies were found to evaluate health-related quality of 
life (HRQoL) after laparoscopic cholecystectomy. Although 94.1% of these studies included PROMs as a 
primary outcome measure, <20% provided level 1 evidence through randomised controlled trials (RCTs). 
There was significant variation in the selection and reporting of PROMs, with no studies declaring patient 
involvement in PROM selection, and 88.2% of studies failing to document the management of missing data 
points, or non-returned surveys (33.3%). In the 6 PROM-validation studies identified, only 5 psychometric 
properties were evaluated, the findings of which were limited due to the small number of studies. This 
systematic review identifies a lack in consistency of study design and PRO reporting in clinical trials. Whilst 
an increasing number of studies are being performed to evaluate PROs, a lack of adherence to existing PRO 
administration and reporting guidelines is continuing to negatively affect study quality. We recommend that 
future clinical trials utilizing PROs should adhere to established comprehensive guidelines as described.
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Introduction
Cholecystectomy is the only definitive treatment for 
patients with symptomatic gallstones, with laparoscopic 
cholecystectomy being the current gold standard (1-3). In 
the UK alone over 60,000 cholecystectomies are performed 
annually, equivalent to approximately 100 procedures per 
100,000 population (1), and more than 200 per 100,000 
population in parts of Europe, and North America (1,4,5). 
Despite the therapeutic benefits of surgery and the potential 
economic savings in preventing further morbidity from 
gallstone disease, laparoscopic cholecystectomy is not 
without risks (2).
Patient reported outcomes (PROs) provide a means of 
measuring various outcomes such as clinical symptoms, 
patient satisfaction and health-related quality of life 
(HRQoL) from a patient’s perspective subjectively (6,7). 
Validated questionnaires or patient reported outcome measures 
(PROMs) are often used to collect PRO data (8). In the 
National Health Service (NHS) in England, this process has 
been adopted as mandatory practice for measuring HRQoL 
in hip and knee replacement surgery, groin hernia repair 
and varicose vein surgery since April 2009 (9). In addition 
to comparing the quality of services across healthcare 
providers, the collection of PROs can also assist patients 
and clinicians in clinical decision making; by monitoring 
illness, and the effectiveness of treatment (9-11).
The primary aim of this systematic review was to 
identify and critically appraise all historic studies evaluating 
patient reported HRQoL, in adult patients, undergoing 
laparoscopic cholecystectomy for symptomatic gallstones.
The secondary aim was to perform a quality assessment 
of cholecystectomy-specific PROM-validation studies using 
the Consensus-based Standards for the selection of health 
Measurement INstruments (COSMIN) checklist (12).
Methods
Search strategy
A search for all relevant literature was performed using 
PubMed, Google™ Scholar, the Cochrane Library, and 
MEDLINE (Ovid) databases in April 2016, and updated 
in September 2017 to include CINAHL (EBSCO), 
EMBASE (Ovid), and PsychINFO (Ovid). The following 
search criteria modified from those developed by the 
Oxford PROM Group in 2010 (13), were used to identify 
relevant studies: (cholelithiasis.mp. or cholecystitis.mp. or 
cholecystolithiasis.mp. or gallstone*.mp. or gall stone*.mp. 
or gallbladder*.mp. or gall bladder*.mp. or biliary colic.mp. 
or biliary sludge.mp. or cholecystectomy.mp.) and ((HR-
PRO or HRPRO or HRQL or HRQoL or QL or QoL 
or PROM or PRO).ti,ab. or quality of life.mp. or (health 
index* or health indices or health profile*).ti,ab. or health 
status.mp. or ((patient or self or child or parent or carer or 
proxy) adj (appraisal* or appraised or report or reported 
or reporting or rated or rating* or based or assessed or 
assessment*)).ti,ab. or ((disability or function or functional 
or functions or subjective or utility or utilities or wellbeing 
or well being) adj2 (index or indices or instrument or 
instruments or measure or measures or questionnaire* or 
profile or profiles or scale or scales or score or scores or 
status or survey or surveys)).ti,ab.).
The search was performed without date restrictions but 
was limited to full-text articles. Due to the availability of 
resources the search was also limited to articles available in 
the English language, or English translation. Only studies 
with an adult population over 18 years of age were included. 
The bibliographies of studies included were also reviewed.
Study selection
Studies identified through the search strategy were assessed 
for inclusion, initially by title and abstract, and subsequently 
through full text review (P Daliya and EH Gemmill). Studies 
were only included where the outcome measure of HRQoL 
formed either a primary or secondary study aim. Only 
studies reporting on patients undergoing cholecystectomy 
for symptomatic gallstones, in which at least one study 
population underwent a conventional 4-port laparoscopic 
cholecystectomy (CLC) were included. Studies which 
reported ‘exclusively’ on patients with biliary malignancy, and 
the complications of gallstone disease, such as gallbladder 
necrosis, perforation, pancreatitis, and choledocholithiasis 
were excluded due to the potential variability of patient 
populations and management of these groups.
Validation studies involving either the development or 
assessment of cholecystectomy-specific PROMs were also 
included but analysed separately. Review articles such as 
meta-analyses and systematic reviews were excluded, as 
were case reports, editorial comments and letters. Duplicate 
studies and populations were cross-referenced and removed. 
Figure 1 demonstrates the preferred reporting items for 
systematic reviews and meta-analysis (PRISMA) flow 
diagram (14).
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Figure 1 Preferred reporting items for systematic reviews and meta-analysis [PRISMA (14)] flow diagram.
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Data extraction
Two independent reviewers (P Daliya and EH Gemmill) 
extracted data from the included studies, with discrepancies 
resolved by a third and fourth (DN Lobo and SL Parsons). 
Data were collected on the details of the publication (author 
names, year of publication, level of evidence and study 
type, number of centres involved, and country), patient 
characteristics within each study (sample size, diagnoses, 
mean age, and gender), and PROM-specific details (PRO 
instruments used, PRO concepts and scoring methodology, 
and survey distribution, response, and follow-up). An 
assessment of bias was performed on all non-validation 
studies utilising the revised Cochrane risk-of-bias tool for 
randomised trials (RoB 2.0) (15), and the Risk Of Bias In 
Non-randomised Studies – of Interventions (ROBINS-I) 
assessment tool (16), as appropriate.
Quality assessment of cholecystectomy-specific validation 
studies
The assessment of the quality of PROM-validation studies 
was performed using the COSMIN checklist; a critical 
appraisal tool which was devised as part of a Delphi study 
to help evaluate the methodological quality of studies on 
PROs (12,17). The checklist uses a standardised descriptive 
framework to assess each of 9 measurement properties 
(internal consistency, reliability, measurement error, content 
validity, structural validity, hypothesis testing, cross-cultural 
validity, criterion validity, responsiveness) against quality 
markers. Each measurement property, where relevant, 
was assessed by completing between 1–18 items on the 
checklist. A 4-point scoring system (“poor”, “fair”, “good”, 
and “excellent”) specifically designed by COSMIN for 
systematic reviews of measurement properties was used to 
grade each item (12). An overall score for each measurement 
property was summarised on a “worst score counts” basis, 
i.e., where a score of “good” or “excellent” was deemed 
as evidence in support of adequate methodological 
quality for that study and “poor” or “fair” as inadequate 
methodological quality (12).
Registration of review
The study proposal was registered (Reg. No. CRD42016048211) 
with the PROSPERO database (www.crd.york.ac.uk/prospero). 
This was amended subsequently to include the additional 
databases used, and the specifications required to complete a 
COSMIN analysis on PROM-validation studies.
Results
A total of 10,615 articles were identified and screened by 
title and abstract review. Of these, 148 remaining articles 
underwent full text review for eligibility. Details on the use 
of a PRO questionnaire were frequently found to be lacking, 
or specifics on the study population such as diagnoses, or 
intervention were also not defined in some cases. Further 
details on study exclusion are as described in the PRISMA 
flow diagram (Figure 1) (14).
A total of 57 studies were identified as utilising PROMs 
in patients undergoing laparoscopic cholecystectomy, 
of which 6 of these were identified as validation studies 
researching the psychometric properties for PROMs in 
patients undergoing laparoscopic cholecystectomy (18-23).
Study quality
Of the 51 non-validation (24-35) studies (36-50) identified 
(51-74), the majority were performed in the last decade 
(62.7%), in Europe (60.8%), and as single centre studies 
(60.8%). Almost 20% provided level 1 evidence through 
randomised controlled trials (RCTs), but the majority 
were conducted as either prospective cohort or case 
control studies. All included trials specified the inclusion 
of patients with symptomatic gallstone disease, although 
further analyses identified significant heterogeneity in 
this definition which also included choledocholithiasis, 
pancreatitis, biliary dyskinesia, and incidental biliary 
tumours (Table 1).
There was significant variation in the selection of 
PROMs as reflected by the differing study outcomes, 
however the 36-item Short Form survey (SF-36) generic 
measure, European Quality of Life Five Dimensions 
Questionnaire (EQ5D) utility measure, gastrointestinal 
quality of life index (GIQLI) disease-specific measure, 
and visual analogue pain scores (VAPS), featured the most 
frequently. Study samples in 18 studies (35.3%) were found 
to be ≤100, although these ranged from between 31 to 
100 patients, with 5 studies describing a population of <60 
patients (25,35,49,51,58).
Risk of bias assessment
A risk of bias assessment demonstrated very few studies with 
a consistently low risk of bias across all domains. Although 
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Table 1 Summary of study characteristics (characteristics of each of 
the 51 non-validation studies)
Characteristics  n %
Year of publication
1991–2000 6 11.8
2001–2010 13 25.5
2011–2017 32 62.7
Origin of study
Europe 31 60.8
Africa 1 2.0
Asia 9 17.6
North America 8 15.7
Intercontinental 2 3.9
Level of evidence & study type
Level 1: randomized controlled trials 10 19.6
Level 2: prospective cohort studies 40 78.4
Level 3: case control studies 1 2.0
Number of study sites involved
1 31 60.8
2 8 15.7
3 4 7.8
5 3 5.9
>5 5 9.8
Diagnoses*
Cholelithiasis 38 74.5
Acute and chronic cholecystitis 18 35.3
Biliary polyps 9 17.6
Biliary dyskinesia 5 9.8
Choledocholithiasis 8 15.7
Gallstone pancreatitis 9 17.6
Gallbladder tumour 2 3.9
Not specified (symptomatic gallstone disease) 10 19.6
Sample size
1–100 18 35.3
101–200 15 29.4
201–300 8 15.7
301–400 4 7.8
Table 1 (continued)
Table 1 (continued)
Characteristics  n %
401–500 2 3.9
>500 4 7.8
PRO as an outcome measure
Primary outcome 39 76.5
Secondary outcome 3 5.9
Primary & secondary outcome 9 17.6
Number of PROs measured*
1 18 35.3
2 17 33.3
>2 16 31.4
When PRO was measured
Pre- and post-operatively 40 78.4
Post-operatively only 10 19.6
Not specified 1 2.0
PRO instruments used*
HRQoL measure
EuroQoL EQ5D 8 15.7
EQVAS 3 5.9
Short form 8 2 3.9
Short form 12 4 7.8
Short form 36 17 33.3
NHPQ 6 11.8
PESQ 1 2.0
Hospital anxiety and depression scale 1 2.0
PGWB 2 3.9
MOS-24 1 2.0
PROMIS-10 1 2.0
Linear analog self-assessment 1 2.0
SFD-LC 1 2.0
State-Trait inventory 1 2.0
Health index 1 2.0
SOMS 2 3.9
Gastrointestinal quality of life index 17 33.3
CSQ 1 2.0
Gastrointestinal symptom survey 1 2.0
Table 1 (continued)
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randomisation was performed well to minimise selection 
bias in the majority of studies, blinding was performed quite 
poorly overall. Where a number of studies employed special 
dressings to blind patient participants against intervention 
identification, some comparative outcomes were unable to 
be realistically blinded against due to the specific outcomes 
studied (27,28,33,42,44,45,51,71). These included the 
comparison of inpatient and outpatient cholecystectomy 
(28,34,42,44), and the measure of cosmesis (33,39,45,51). 
Three studies were underpowered, having failed to 
recruit sufficient participants (27,30,48), and 12 presented 
incomplete data having either excluded surveys with missing 
responses or discounted those lost to follow-up (30,31,34, 
36,40,46,47,50,53,57,65,68) (Tables 2,3).
PROMs
The majority of studies (94.1%) included PROs as a 
primary outcome measure, and over 60% of studies 
measured more than two PRO concepts. These included 
HRQoL, cosmesis and body image, post-operative pain, 
sexual function and patient satisfaction (Table 4). Forty 
studies (78.4%) were set up with the intent to compare two 
or more different operative techniques for cholecystectomy. 
All studies were performed for research purposes with no 
involvement of patient groups to aid PROM selection. 
Profile scores rather than single indicator or index numbers 
were used to describe PROs in the majority of studies, 
with only 25.5% of studies using both generic and disease-
specific PROMs, and only 60.8% of studies used PROMs 
which were validated with demonstrable evidence of this. A 
significant proportion of studies (88.2%) did not discuss the 
management of missing responses within surveys, 21.6% 
did not consider baseline or pre-operative PROM scores 
for their population, and 33.3% were not clear about their 
survey return rate. Full study characteristics are available in 
the Table S1.
Validation studies
Of the 6 PROM-validation studies identified, 4 reported 
on the gastrointestinal quality of life index (GIQLI) 
(18-21), whereas one study reported on the Otago 
G a l l s t o n e s  C o n d i t i o n  S p e c i f i c  Q u e s t i o n n a i r e 
(CSQ) (22), and one on the Gallstone Impact Checklist 
(GIC) (23). These studies included original validation 
studies (18,22,23), in addition to translations in to other 
languages (19-21).
Table 1 (continued)
Characteristics  n %
Gallstone symptom checklist 1 2.0
Visual analogue scale 2 3.9
Cosmesis & body image measure
Body image scale 1 2.0
Body image questionnaire 4 7.8
Photograph series questionnaire 3 5.9
POSAS 1 2.0
Likert scale 1 2.0
Visual analogue scale 2 3.9
Pain measure
Visual analogue pain scale 15 29.4
McGill pain questionnaire 3 5.9
Satisfaction measure
Likert scale 1 2.0
Visual analogue scale 1 2.0
Distribution of PROs*
Clinic 23 45.1
Post 27 52.9
Ward 10 19.6
Phone 7 13.7
Email 1 2.0
Researcher 6 11.8
Not specified 10 19.6
Post-operative PRO return rate
80–100% 23 45.1
60–79% 9 17.6
<60% 4 7.8
Not specified 15 29.4
*, may be ≥1 per study. EuroQoL EQ5D, European Quality of 
Life Five Dimensions Questionnaire; EQVAS, European Quality 
of Life Visual Analogue Scale; NHPQ, Nottingham Health 
Profile Questionnaire; PESQ, Patients’ Experience of Surgery 
Questionnaire; PGWB, Psychological General Well-Being index; 
MOS-24, Medical Outcomes Study 24-item Short Form Health 
Survey; PROMIS-10, Patient-Reported Outcomes Measures 
Information System-10; SFD-LC, Symptom, Frequency and 
Distress questionnaire-LC version; SOMS, Surgical Outcomes 
Measurement System; CSQ, Otago Gallstones Condition 
Specific Questionnaire; POSAS, Patient and Observer Scar 
Assessment Scale.
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COSMIN analysis
The commonest measurement properties analysed were 
internal consistency and reliability (all 6 PROM-validation 
studies), and responsiveness (5 of 6 studies). Only 2 studies 
scored either “good” or “excellent” for internal consistency, 
describing adequate methodological quality (20,21), 
whereas the other 4 studies rated as either “fair” or “poor”, 
describing inadequate methodological quality. The summary 
scores for each measurement property, for each study are 
shown in Table 5. No studies performed an assessment of 
“measurement error”, “hypotheses testing”, or “criterion 
validity”. The methodological qualities assessed for each 
study are summarised in Table S2.
Due to the limited number of PROM-validation studies 
identified, the quality of the measurement instruments 
identified was not assessed against the “criteria for good 
measurement properties” as recommended by the COSMIN 
guidelines (76) and, therefore, preclude recommendation of 
a specific PROM for use in laparoscopic cholecystectomy
Discussion
PROM selection
A recent systematic review of RCTs evaluating PROs after 
cholecystectomy (77) utilized the International Society of 
Quality of Life Research (ISOQOL) checklist to assess the 
quality of reporting in their evaluated studies. The authors 
demonstrated that, despite the availability of the ISOQOL 
checklist since 2013, the majority of studies did not adhere 
to guidelines, and demonstrated high bias and poor quality 
reporting of PROs (77).
In contrast, we analyzed all clinical trials evaluating 
HRQoL after laparoscopic cholecystectomy so as not to 
exclude the majority of clinical studies (>80%) which were 
non-RCTs. We therefore used the amended checklist as 
described by Patrick and Erikson (75) in the Cochrane 
Handbook, to describe and assess the identified studies. 
Much like Mueck et al. (77) the present review also 
demonstrated significant variability in PRO reporting. 
Across the clinical trials included, a wide variety of concepts 
were evaluated in addition to HRQoL, via a number of 
different PRO instruments (Table 1). This variation reflects 
the lack of specific recommendations in PROM selection 
in patients undergoing laparoscopic cholecystectomy, and 
the variation in study rationale which in itself can impact 
PROM selection.
Each study seemingly selected PRO instruments T
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Table 4 Summary of patient reported outcomes measures (PROMs) used in the clinical trials (n=51)
Variable n %
What were the PROs measuring?
What concepts were the PROs used in the study measuring?*
Health-related quality of life (HRQoL) 51 100
Cosmesis & body image 12 23.5
Pain 18 35.3
Sexual function 1 2.0
Satisfaction 5 9.8
What rationale (if any) for the selection of concepts or constructs did the authors provide?
To compare PROs between 2 or more cholecystectomy types 40 78.4
To assess validity of a monitoring system 1 2.0
To assist patient selection between 2 or more cholecystectomy types 1 2.0
To correlate clinical findings predictive with a better quality of life (QoL) 8 15.7
To incorporate QoL into routine clinical practice 1 2.0
Were patients involved in the selection of outcomes measured by the PROs?
No 51 100
Omissions
Were there any important aspects of health or QoL that were omitted in this study?*
Validated disease-specific HRQoL instrument not considered 32 62.7
Validated generic HRQoL instrument not considered 7 13.7
Baseline or pre-operative QoL score not considered 11 21.6
Management of missing HRQoL responses not discussed 45 88.2
Percentage of surveys returned not discussed or unclear 17 33.3
If randomized trials and other studies measured PROs, what were the instruments’ measurement strategies?
Did investigators use HRQoL instruments that yield a single indicator or index number, or a profile score?*
Profile scores 45 88.2
Single indicator/index number (overall score) 27 52.9
If investigators measured PROs, did they use specific or generic measures, or both?
Specific 9 17.6
Generic 29 56.9
Both 13 25.5
Who exactly completed the instruments?
Patient 50 98.0
Patient & interviewer 1 2.0
Table 4 (continued)
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Table 4 (continued)
Variable n %
Did the instruments work in the way they were supposed to work?
Had the instruments used been validated previously, and was evidence of prior validation for use in this 
population presented?*
Validated, but not evidenced in the study 28 54.9
Validated, and evidenced in the study 31 60.8
Not validated or evidenced 8 15.7
Were the instruments re-validated in this study?
No 49 96.1
Yes 2 3.9
Did the instruments work in the way they were supposed to work—ability to measure change?
Are the PROs able to detect change in patient status, even if those changes are small?
Yes 51 100
Can you make the magnitude of effect understandable to readers?
Can you provide an estimate of the difference in patients achieving a threshold of function or improvement, 
and the associated number needed to treat?
Possible from the data presented 20 39.2
Not possible from the data presented 31 60.8
*, may be ≥1 per study. Checklist amended from that used by Patrick and Erikson (75) in the Cochrane Handbook. PROs, patient reported 
outcomes; QoL, quality of life.
Table 5 COSMIN (Consensus-based Standards for the selection of health Measurement INstruments) analysis (methodological quality of each 
study per Patient Reported Outcome Measure questionnaire per measurement property)
Study
Internal 
consistency
Reliability
Measurement 
error
Content 
validity
Structural 
validity
Hypotheses 
testing
Cross-cultural 
validity
Criterion 
validity
Responsiveness
GIQLI: Gastro-Intestinal Quality of Life Index
Eypasch, 1995 (18) Fair Poor – Fair – – – – Poor
Lien, 2007 (19) Poor Poor – – – – Fair – Poor
Quintana, 2001 (20) Excellent Poor – – – – Poor – Poor
Sandblom, 2009 (21) Good Fair – – – – Poor – Poor
CSQ: Otago Gallstones Condition Specific Questionnaire
Chen, 2006 (22) Poor Poor – Fair – – – – –
GIC: Gallstone Impact Checklist
Russell, 1996 (23) Poor Poor – Fair – – – – Poor
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based on the re levance to  pr imary or  secondary 
outcomes. However, despite the availability of guidance 
documentation on the use of PROs in clinical trials (11,75), 
only 25% of the studies reviewed measured both generic 
and condition-specific PROs. Justification on the rationale 
for selection was also varied, with documentation in only 
16 papers. These reasons included the following: due to 
the availability of a standardized comparative reference 
population (30,56,59,73), pre-existing validation within the 
same or similar cohort (32,40,47,54,56,58,65,71), easier 
survey application or user friendliness (26,34), adherence 
to recommended guidelines (although these were not 
specified) (43), to aid the calculation of specific outcomes 
which are dependent on a specific type of PROM, i.e., 
quality-adjusted life year (QALY) (61), or prior knowledge 
of the psychometric quality of the chosen instrument (28).
PROM dissemination
To our knowledge the completion of PRO surveys in all 
specified studies was either by the patients themselves 
or with the aid of a dedicated researcher. These were 
administered to patients in person, by post, or over 
the phone via traditional paper surveys. None of the 
studies included described the use of digital, electronic, 
or automated PRO mediums, despite recent advances 
in technology. Many alternative modalities are now 
available including web-based patient surveys, tablet-based 
applications, or voice activated phone surveys to name 
a few (78).
Whilst these more modern methods have the potential 
to increase the efficiency of data collection, reduce 
transcription errors caused by data entry, aid data analysis, 
and reduce missing data points within surveys, they also 
have some significant limitations. Licensing costs for 
validated surveys can be significant given the importance 
of data security, and users must be technologically adept or 
receive appropriate training (78).
All studies collected PRO data prospectively for research 
purposes although 4 (40,56,61,62) of the 8 Swedish studies 
also utilized their national registry [GallRiks (79)] to 
aid data collection as standard practice, which was also 
performed prospectively. This is significant given that 
retrospective data collection is more likely to add bias 
due to poor recollection and a potential increase in data 
gaps (78).
PRO analysis
In trials where both profile and index score calculations 
were possible, there was no explanation given when only 
one measurement strategy was used. Although profile scores 
can provide useful information on multiple PRO domains 
such as physical (pain, mobility, activity) and psychological 
(mood, energy, anxiety or depression) functioning, they are 
not always possible nor do they provide additional benefit 
when compared with index or indicator scores in some 
studies (75). These overall scores can provide sufficient 
information to demonstrate a change in HRQoL and can be 
particularly useful when PROs are used as markers for other 
outcomes such as cost effectiveness information or QALY 
to assess service quality (75).
Although the majority of studies commented on the 
return rate of surveys, which demonstrated good overall 
patient participation and low attrition, very few studies 
commented on the management of incomplete returned 
HRQoL surveys. This is significant as the imputation of 
results into missing data points or conversely the extraction 
of incomplete surveys can introduce bias (8,78). Similarly 
the lack of pre-operative or baseline population values 
prevent a calculation in change from baseline; a concept 
useful in demonstrating unbiased improvements or 
deterioration from the population norm (80).
Review of methodological quality
The 2011 review by the Oxford PROM Group appraised 7 
PRO instruments on methodological quality, and performed 
an expert panel review on their suitability as clinical care 
evaluation tools (11). This review recommended one of two 
generic health measures (SF36), one of one preference-
based measures (EQ5D), and one of four condition-
specific measures (CSQ) as PRO assessment tools in 
patients undergoing cholecystectomy. Interestingly, these 
recommended PROs were noted to have little or no 
evidence of good methodological quality on assessment 
of their psychometric properties (reproducibility, 
internal consistency, content validity, construct validity, 
responsiveness, interpretability, and the presence of floor 
to ceiling effects). Similarly, our COSMIN review of the 
6 PROM-validation studies identified, also demonstrated 
fair to poor methodological quality in the majority of the 
psychometric properties evaluated (internal consistency, 
reliability, content validity, cross-cultural validity, and 
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responsiveness). Unfortunately, the identification of 
such few validation studies of poor quality obviated the 
possibility of commenting on the quality of the identified 
PRO instruments. This has a significant bearing on 
recommending PRO instruments as guidelines suggest that 
studies of poor quality provide little value (12).
Psychometric properties in detail
Internal consistency was analysed in all 6 PROM-validation 
studies. Despite all studies achieving a Cronbach’s alpha 
≥0.7 for their global rating score, COSMIN analysis 
demonstrated poor internal consistency. This was accounted 
for by studies failing to describe their management of 
missing data points (18), and the use of inadequate sample 
sizes (19,22,23). Further inspection also demonstrated that 
where global rating scales achieved an optimum acceptable 
value ≥0.7 for Cronbach’s alpha (7,11,76), a measure of 
scale reliability, individual dimension scores were found to 
be <0.7 in some instances (19,23) demonstrating poor inter-
correlation within scales.
Studies deemed to have poor reliability (a measure of 
scale stability) had small sub-group sample sizes (18), and 
inadequate intervals (18) [such as 48 hours, instead of the 
recommended minimum of 2 weeks (81)]. The performance 
of significant interventions between test-retest readings 
[surgical management (20,23)], a change in environment 
[ward-based to clinic room (22)],  or a move from 
researcher-led surveys, to postal surveys (22) also affected 
the measure of scale reliability (76).
The three studies (18,22,23) which measured content 
validity performed well overall, only missing out on a score 
of excellent due to minor methodological flaws in study 
design, such as non-reporting of missing data, or a lack of 
sub-group demographics to detail the constitution of the 
expert review panel.
Three studies involved a translation of the GIQLI 
questionnaire (19-21). Two were translated from the original 
German GIQLI to either Spanish (20) or Swedish (21), 
and one was translated from the original English GIQLI 
to Mandarin Chinese (19). Two studies commented on 
translation alone and did not meet the full criteria for 
cross-cultural validity (19,21). Information on the expertise 
of translators was limited to language expertise alone in 
all studies. There was no description on the expertise of 
translators with respect to the disease process studied, or 
the construct measured. No mention was made of whether 
translators worked independently, and all studies performed 
the minimum requisite of one forward and backward 
translation, using a minimum or 2 translators. The translation 
studies did not describe any pre-test process (19,21), although 
in the one study that analysed full cross-cultural validity, 
minimal information was provided of the study sub-group, 
reducing the overall methodological score to “poor” (20).
All studies evaluated scored poor for responsiveness due 
to the absence of detail on study hypotheses (18-21,23). 
This was because none of the studies had commented on 
or quantified the expected direction or magnitude of study 
outcomes a-priori (76).
Strengths and limitations
Although other assessments of methodological quality 
are available, the COSMIN analysis is to our knowledge 
the most standardized method of assessment of PROM-
validation studies given the stringent criteria and associated 
guidelines.
Due to our limitation of resources the exclusion of 
studies performed in languages other than English may 
have prevented the identification of some PRO and PROM-
validation studies.
Conclusions
This review of PRO studies assessing HRQoL and PROM-
validation studies in patients undergoing laparoscopic 
cholecystectomy identifies a lack in consistency of study 
design and PRO reporting in clinical trials. Whilst an 
increasing number of studies are being performed to 
evaluate PROs, a lack of adherence to existing PRO 
administration and reporting guidelines is continuing 
to negatively affect study quality. We recommend 
future clinical trials utilizing PROs should adhere to 
established comprehensive guidelines as described in the 
CONSORT (Consolidated Standards of Reporting Trials) 
PRO extension (6), and the SPIRIT (Standard Protocol 
Items: Recommendations for Interventional Trials) PRO 
extension (80). Researchers should aim to re-validate PRO 
instruments in their study population (75,80) and, therefore, 
ensure selected PROMs have good methodological 
quality (76).
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Supplementary
Table S1 Study characteristics (detailed information of each of the 51 non-validation studies)
Author, year Study type
No. of 
centres
N Diagnosis Intervention Control Study outcome/s
Abd Ellatif, 2013 (24) RcT 1 250 Cholelithiasis SALC CLC HRQoL, operative time, pain, cosmesis, blood loss, 
resumption diet, LOS, DRNA
Ainslie, 2003 (25) RCT 1 40 Cholelithiasis MPLC CLC Operative time, analgesia, pain, pulmonary function, 
HRQoL, serum stress response
Aspinen, 2017 (26) RcT 2 109 Cholelithiasis MC CLC HRQoL
Barkun, 1992 (27) RCT 5 70 Cholelithiasis MC CLC LOS, DRNA, pain, HRQoL, operative time, conversion, 
resumption diet
Barthelsson, 2008 (28) RcT 1 73 Cholelithiasis Outpatient CLC Inpatient CLC Pain, anxiety/distress symptoms, HRQoL
Bingener, 2015 (29) RcT 1 110 Cholelithiasis SPLC CLC Pain, HRQoL, serum cytokines, heart rate variability
Bitzer, 2008 (30) Longitudinal cohort 2 205 Cholelithiasis, cholecystitis CLC none HRQoL, symptoms, satisfaction
Borchert, 2012 (31) Observational cohort 1 275 Cholelithiasis TVC CLC Pain, analgesia, HRQoL, sexual function
Brown, 2013 (32) Randomised cohort 1 79 Cholelithiasis, biliary dyskinesia SILC CLC HRQoL, LOS, operative costs
Bucher, 2011 (33) RcT 1 150 Cholelithiasis, cholecystitis, pancreatitis, 
incidental cholangiocarcinoma
LESS CLC Cosmesis, pain, analgesia, morbidity, operative time, 
port enlargement, HRQoL, LOS, DRNA, operative costs
Burney, 2002 (34) Observational cohort 1 140 Cholelithiasis Outpatient CLC Inpatient CLC HRQoL
Chen, 2005 (35) Prospective cohort 1 51 Cholelithiasis, chronic cholecystitis CLC OC HRQoL
Cleary, 1995 (36) Observational cohort 1 391 Cholelithiasis, cholecystitis CLC OC HRQoL, morbidity
Finan, 2006 (37) Observational cohort 1 104 Cholelithiasis CLC none HRQoL, symptoms
Harju, 2007 (38) RcT 1 157 Cholelithiasis MLC CLC HRQoL
Hauters, 2013 (39) Observational cohort 9 104 Cholelithiasis SILC CLC Operative time, morbidity, HRQoL, cosmesis, 
satisfaction
Howie, 2017 (40) Observational cohort 14 4,021 Cholelithiasis CLC, OC, MLC none Pain, symptoms, HRQoL, long-term outcomes
Hsueh, 2011 (41) Observational cohort 2 297 Cholelithiasis, cholecystitis CLC, OC none HRQoL
Johansson, 2006 (42) RcT 1 107 Cholelithiasis Outpatient CLC Inpatient CLC HRQoL
Keus, 2008 (43) RcT 1 257 Cholelithiasis CLC SIC HRQoL, cosmesis
Keulemans, 1998 (44) RCT 1 80 Cholelithiasis Outpatient CLC Inpatient CLC HRQoL, readmission
Kudsi, 2017 (45) RCT 8 138 Cholelithiasis, cholecystitis, biliary 
polyps, biliary dyskinesia
RSSC CLC HRQoL, satisfaction, cosmesis, perioperative outcomes
Kum, 1996 (46) Observational cohort 1 478 Cholelithiasis, cholecystitis CLC acute 
cholecystitis
CLC cholelithiasis Pain, fatigue, HRQoL, morbidity
Lamberts, 2015 (47) Observational cohort 3 552 Cholelithiasis CLC None Pain, HRQoL, symptoms
Leung, 2012 (48) RcT 3 79 Choledocholithiasis, cholecystitis, 
pancreatitis
SILC CLC HRQoL, cosmesis, pain, morbidity, cost, efficiency
Lirici, 2011 (49) Observational cohort 2 40 Cholelithiasis LESS CLC HRQoL, cosmesis, pain, LOS, operative time, 
conversion, operative difficulty, morbidity
Liu, 2016 (50) RCT 1 245 Cholelithiasis 3-port LC CLC HRQoL, cosmesis, pain, LOS, costs
Ma, 2011 (51) RCT 1 43 Cholelithiasis, biliary polyps, biliary 
dyskinesia
SPLC CLC Pain, HRQoL, cosmesis, operative time, LOS, morbidity
Matovic, 2012 (52) Observational cohort 1 120 Cholelithiasis CLC OC HRQoL
McLean, 2017 (53) Observational cohort 1 234 Cholelithiasis CLC, OC none HRQoL, satisfaction, symptoms
Mentes, 2001 (54) Observational cohort 1 67 Cholelithiasis CLC symptomatic 
gallstones
CLC asymptomatic 
gallstones
HRQoL
Nilsson, 2004 (55) RCT 5 726 Cholelithiasis MC CLC HRQoL, costs
Pålsson, 2011 (56) Observational cohort 5 330 Cholelithiasis, cholecystitis, pancreatitis, 
choledocholithiasis, biliary polyps, biliary 
tumours
CLC None HRQoL
Phillips, 2012 (57) RCT 10 197 Cholelithiasis, biliary polyps, biliary 
dyskinesia
SILC CLC Pain, cosmesis, HRQoL, operative time
Plaisier, 1995 (58) Observational cohort 1 31 Cholelithiasis CLC OC HRQoL, symptoms
Plannells Roig, 2013 (59) Observational cohort 1 99 Cholelithiasis, cholecystitis, pancreatitis, 
choledocholithiasis
CLC, OC, LESS None Disease impact, HRQoL
Reibetanz, 2013 (60) Observational cohort 1 100 Cholelithiasis, cholecystitis SPLC CLC HRQoL, cosmesis, satisfaction, operative time, 
morbidity, LOS
Rosenmüller, 2017 (61) RCT 2 355 Cholelithiasis, cholecystitis, pancreatitis, 
choledocholithiasis
SIC CLC HRQoL, costs, pain, morbidity, operative time, LOS, 
conversion, readmissions
Rydbeck, 2015 (62) Observational cohort 6 919 Cholelithiasis, cholecystitis, pancreatitis, 
choledocholithiasis
CLC, OC None HRQoL
Saad, 2013 (63) RcT 1 105 Cholelithiasis SPLC, mini-
laparoscopic LC
CLC Pain, HRQoL, cosmesis, satisfaction
Sadati, 2016 (64) Observational cohort 2 100 Cholelithiasis, cholecystitis CLC OC HRQoL
Shi, 2011 (65) Prospective cohort 2 353 Cholelithiasis CLC None HRQoL
Squirrell, 1998 (66) RcT 1 100 Cholelithiasis CLC SIC HRQoL, pain, metabolic & respiratory response
Sulu, 2015 (67) RcT 1 60 Cholelithiasis SPLC CLC HRQoL, satisfaction
Tani, 2015 (68) Observational cohort 1 127 Cholelithiasis, biliary polyps CLC None HRQoL, pain
Teubner, 2016 (69) Prospective cohort 2 66 Cholelithiasis SILC CLC HRQoL, cosmesis, satisfaction
Topcu, 2003 (70) Case control 1 200 Cholelithiasis, biliary polyps, 
cholecystitis, pancreatitis, 
choledocholithiasis
CLC OC HRQoL, clinical outcomes
Vetrhus, 2004 (71) RCT + crossover 3 137 Cholelithiasis CLC, OC Observation HRQoL, pain
Wagner, 2013 (72) Observational cohort 1 222 Cholelithiasis, biliary polyps, cholecystitis SPLC CLC HRQoL, morbidity
Wanjura, 2016 (73) Observational cohort 1 451 Cholelithiasis, biliary polyps, 
cholecystitis, pancreatitis, 
choledocholithiasis
Cholecystectomy None HRQoL
Zapf, 2013 (74) Observational cohort 3 100 Cholelithiasis, biliary polyps, pancreatitis, 
biliary dyskinesia, choledocholithiasis
CLC None HRQoL, pain
RCT, randomised controlled trial; RcT, randomised clinical trial; CLC, conventional laparoscopic cholecystectomy; LC, laparoscopic cholecystectomy; LESS, laparoendoscopic single site cholecystectomy; MC, 
minilaparotomy cholecystectomy; MPLC, micro-puncture laparoscopic cholecystectomy; OC, open cholecystectomy; RSSC, robotic single-site cholecystectomy; SALC, single-access laparoscopic cholecystectomy; 
SIC, small incision cholecystectomy; SILC, single incision laparoscopic cholecystectomy; SPLC, single port laparoscopic cholecystectomy; TVC, transvaginal cholecystectomy; LOS, length of stay; DRNA, duration to 
return to normal activity; HRQoL, health related quality of life.
Table S2 COSMIN (Consensus-based Standards for the selection of health Measurement Instruments) analysis (summary of methodological 
qualities assessed for each study)
Study
Eypash, 
1995 (18)
Lien, 
2007 (19)
Quintana, 
2001 (20)
Sandblom, 
2009 (21)
Chen, 
2006 (22)
Russell, 
1996 (23)
PRO instrument GIQLI GIQLI GIQLI GIQLI CSQ GIC
A. Internal consistency: Cronbach’s alpha (calculated for each 
subscale). Extent to which items in a (sub) scale are correlated 
(measuring the same construct)
Y Y Y Y Y Y
B. Reliability: ICC. Extent to which patients can be distinguished 
from each other despite measurement errors (proportion of the total 
variance in measurement properties which is due to ‘true’ differences 
between patients)
Y Y Y Y Y Y
C. Measurement error: systematic and random error of a patient’s 
score that is not attributed to true changes in patient’s disease status
x x x x x x
D. Content validity (face validity & construct validity): degree to which 
content of instrument is adequate reflection of construct measured 
(involves patients/experts in development of PROMs through 
interview, testing, focus groups)
Y x x x Y Y
E. Structural validity: degree to which scores of instrument are 
reflection of dimensionality of construct measured (determined by 
factor analysis)
x x x x x x
F. Hypotheses testing: degree to which scores of instrument are 
consistent with hypotheses based on assumption the instrument 
validly measures what it is meant to (hypotheses must give direction 
& magnitude)
x x x x x x
G. Cross-cultural validity: degree to which performance of items on 
translated questionnaire is an adequate reflection of the performance 
of items on original questionnaire
x Y Y Y x x
H. Criterion validity: extent to which scores on questionnaire relate to 
a gold standard
x x x x x x
I. Responsiveness: ability of a questionnaire to detect clinically 
important changes over time (ability to detect improvement/
deterioration)
Y Y Y Y x Y
J. Interpretability: degree to which you can assign qualitative meaning 
to quantitative scores
x x x x x x
PROs, patient reported outcomes; PROMs, patient reported outcome measures; GIQLI, gastrointestinal quality of life index; CSQ, Otago 
Gallstones Condition Specific Questionnaire; GIC, Gallstone Impact Checklist; ICC, intraclass correlation coefficient; Y, yes; x, no.
